Rosai-Dorfman Disease clinical trials at UCSF

1 research study open to eligible people

Rosai-Dorfman disease is a disorder where immune cells build up. UCSF uses cobimetinib in a study for both children and adults with Langerhans Cell Histiocytosis. This trial examines the drug's effect on similar histiocytic diseases.

Showing trials for

  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    San Francisco, California and other locations

Last updated: